Abstract:
BACKGROUND:The efficacy of amrubicin for relapsed small-cell lung cancer (SCLC) has been reported in previous studies. Few reports, however, describe the efficacy and survival benefit of third-line amrubicin chemotherapy in patients with extensive disease (ED)-SCLC. METHODS:We retrospectively analyzed the clinical records of ED-SCLC patients treated with amrubicin salvage chemotherapy as a third-line chemotherapy between January 2005 and July 2016 (salvage amrubicin group). The efficacy and toxicities of amrubicin were evaluated. Overall survival (OS) in the amrubicin salvage group was compared with OS among ED-SCLC patients treated with at least second-line chemotherapy between May 2000 and July 2016 and without subsequent amrubicin salvage chemotherapy. RESULTS:A total of 18 patients with a median age of 70 years were analyzed in the amrubicin salvage group. The median number of treatment cycles of amrubicin was four. The response rate was 27.8% (95% confidence interval (CI), 7.1%-48.5%), and the disease control rate (DCR) was 66.7% (95% CI, 44.9%-88.4%). Median progression-free survival was 2.9 months (95% CI, 1.0-4.9 months), and median OS after an initial chemotherapy was 18.1 months (95% CI, 10.2-26.0 months). OS in the amrubicin salvage group was significantly longer than in the no-amrubicin group (n = 19; 12.6 months, 95% CI, 11.5-13.8 months, P = 0.005). The frequency of neutropenia greater than grade 3 was 72.2%, with febrile neutropenia developing in 38.9% of patients in the amrubicin salvage group. CONCLUSIONS:Despite a high frequency of febrile neutropenia, amrubicin salvage chemotherapy may improve OS in patients with relapsed ED-SCLC.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Sonehara K,Tateishi K,Fukushima T,Komatsu M,Yamamoto H,Koizumi T,Hanaoka Mdoi
10.1111/1759-7714.13150subject
Has Abstractpub_date
2019-09-01 00:00:00pages
1805-1811issue
9eissn
1759-7706issn
1759-7714journal_volume
10pub_type
临床试验,杂志文章相关文献
Thoracic Cancer文献大全abstract::Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pru...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13275
更新日期:2020-02-01 00:00:00
abstract:BACKGROUND:To investigate the correlation between mesenchymal-epithelial transition factor (C-Met) and human epidermal growth receptor 2 (HER2) protein expression in primary lung adenocarcinoma tissues. METHOD:A total of 1479 resected primary lung adenocarcinoma patients were enrolled in the present study for detectin...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12595
更新日期:2018-04-01 00:00:00
abstract::In recent years, studies have found that E2F1, a downstream effector of caveolin-1 (Cav-1), participates in tumor cell metabolic reprogramming. E2F1 modulates mitochondrial fusion and mitophagy. Bioinformatic analysis has identified the E2F1-MFN2 axis as a regulator of mitophagy. Our data establish a new novel paradig...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13408
更新日期:2020-06-01 00:00:00
abstract:BACKGROUND:Previous studies have reported that soluble fms-like tyrosine kinase-1 (sFlt-1) possesses anti-tumor effects by inhibiting angiogenesis in many cancers. Exosomes can be engineered as delivery vehicles for transferring functional biomolecules, such as proteins, lipids, and nucleic acids (DNA, mRNA, and miRNA)...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13175
更新日期:2019-10-01 00:00:00
abstract::Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9-14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-f...
journal_title:Thoracic cancer
pub_type: 杂志文章,多中心研究
doi:10.1111/1759-7714.12923
更新日期:2019-02-01 00:00:00
abstract:BACKGROUND:The aim of this study was to investigate the patterns and influencing factors of local-regional recurrence of lower thoracic esophageal squamous cell carcinoma (TESCC) after curative resection and to delineate the clinical target volume (CTV) of postoperative radiotherapy (PORT). METHODS:From January 2009 t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12499
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:We investigated the effect of micro-RNA 24 (miR-24) and WWOX on non-small cell lung cancer (NSCLC) cell proliferation and migration in vitro and in vivo. METHODS:We performed bioinformatics analysis and 3' untranslated region luciferase assay to investigate the direct target of miR-24. Proliferation, apopto...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12824
更新日期:2018-12-01 00:00:00
abstract::A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12362
更新日期:2016-09-01 00:00:00
abstract::Bronchomediastinal fistula is an extremely rare complication resulting from diseases such as mediastinitis or mediastinal malignancies. In patients with lung cancer, bronchomediastinal fistula formation has rarely been reported, except during post-chemotherapy or post-radiation therapy complications. An 84-year-old vi...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/j.1759-7714.2012.00167.x
更新日期:2013-08-01 00:00:00
abstract:BACKGROUND:Rab27A and Rab27B are the major components of vesicle fusion and trafficking in exosome secretion and play important roles in tumor progression and metastasis. In addition, Rab27A and Rab27B are associated with tumor prognosis. This study investigated the prognostic roles of Rab27A and Rab27B expression in p...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12919
更新日期:2019-02-01 00:00:00
abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. METHODS:The MeSO-CLICaP registry identified 302 patients with advanced MPM diagnose...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12967
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND:Approximately 8.3-15.9% of patients with clinical stage I non-small cell lung cancer are subsequently shown to have lymph node metastasis. However, the clinical characteristics of patients with lymph node metastasis in China are not fully understood. METHODS:This is a multicenter retrospective analysis of p...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12970
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12762
更新日期:2018-07-01 00:00:00
abstract::After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving therapy with tyrosine kinase inhibitors develop drug resistance through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in epidermal growth factor receptor-mutated and anaplastic lymphom...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12416
更新日期:2017-07-01 00:00:00
abstract::Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12557
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:Metastatic or recurrent thyroid cancer often behaves aggressively, and approximately two-thirds of patients present with radioiodine resistance. Effective therapies to suppress thyroid cancer metastasis are urgently needed. Nevirapine has been proved to suppress tumor growth and induce differentiation in sev...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13211
更新日期:2019-12-01 00:00:00
abstract:BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13622
更新日期:2020-10-01 00:00:00
abstract:BACKGROUND:This study aimed to explore the effects of HMGA2 on cell proliferation and metastases in lung cancer and its underlying mechanism. METHODS:HMGA2 expression in lung cancer tissues and its association with overall survival were analyzed based on data from a public database. The roles of HMGA2 were validated v...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12476
更新日期:2017-09-01 00:00:00
abstract::Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12263
更新日期:2016-03-01 00:00:00
abstract:BACKGROUND:Uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study. METHODS:Eligibility cr...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12360
更新日期:2016-07-01 00:00:00
abstract:BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12454
更新日期:2017-07-01 00:00:00
abstract:BACKGROUND:The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS:All cases of lung cancer included in our prospective database between January 2000 and J...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12790
更新日期:2018-08-01 00:00:00
abstract::In the past decade, a dramatic shift has been witnessed in cancer therapy in China. Although traditional cytotoxic chemotherapy still remains the treatment of choice for many malignancies, targeted therapies are now a component of treatment for many types of cancer, including lung cancer. As molecular target agents ar...
journal_title:Thoracic cancer
pub_type: 杂志文章,评审
doi:10.1111/1759-7714.12243
更新日期:2015-07-01 00:00:00
abstract::Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) ...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13466
更新日期:2020-07-01 00:00:00
abstract:BACKGROUND:Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood....
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12504
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:Few studies have been conducted on the relationship between chronic periodontitis and postoperative pneumonia (POP) in patients with lung and esophageal cancer. Furthermore, it remains controversial as to whether improving the periodontal condition of patients with lung and esophageal cancer before surgery r...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13828
更新日期:2021-01-24 00:00:00
abstract::Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12277
更新日期:2015-11-01 00:00:00
abstract:BACKGROUND:The important role of angiogenesis displaying in tumor development and metastasis has been generally realized. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endostatin (ES) are critical members of angiogenesis modulating the balance between pro-angiogenenic and anti-ang...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12202
更新日期:2015-07-01 00:00:00
abstract:BACKGROUND:Increasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for canc...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12761
更新日期:2018-08-01 00:00:00
abstract::Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13588
更新日期:2020-09-01 00:00:00